gemfibrozil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1285	25812-30-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: gemfibrosil gemfibrozil decrelip lopizid	A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. Molecular weight: 250.34 Formula: C15H22O3 CLOGP: 3.94 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -3.95 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

gemfibrosil
gemfibrozil
decrelip
lopizid

A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Molecular weight: 250.34
Formula: C15H22O3
CLOGP: 3.94
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -3.95
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	79.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	98 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1981	FDA	PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	462.50	40.47	124	344	46519	2311098
Rhabdomyolysis	345.68	40.47	69	399	6635	2350982
Completed suicide	162.88	40.47	47	421	20987	2336630
Drug interaction	115.08	40.47	39	429	29124	2328493
Myalgia	107.07	40.47	35	433	23298	2334319
Blood creatine phosphokinase increased	89.83	40.47	22	446	5114	2352503
Tendon rupture	56.19	40.47	12	456	1506	2356111
Myopathy	55.99	40.47	12	456	1531	2356086
Respiratory arrest	48.21	40.47	14	454	6164	2351453
Acute kidney injury	46.32	40.47	20	448	28102	2329515
Aspartate aminotransferase increased	45.99	40.47	16	452	12596	2345021
Alanine aminotransferase increased	44.32	40.47	16	452	14016	2343601

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	1224.93	47.41	249	505	10841	1735186
Acute kidney injury	475.12	47.41	149	605	34795	1711232
Blood creatine phosphokinase increased	300.72	47.41	78	676	8778	1737249
Drug hypersensitivity	290.23	47.41	85	669	15050	1730977
Myalgia	282.96	47.41	84	670	15574	1730453
Drug interaction	161.27	47.41	64	690	27894	1718133
Asthenia	115.67	47.41	54	700	34616	1711411
Blood triglycerides increased	102.59	47.41	26	728	2574	1743453
Completed suicide	92.25	47.41	37	717	16275	1729752
Myositis	83.23	47.41	20	734	1583	1744444
Blood cholesterol increased	79.79	47.41	22	732	3004	1743023
Muscular weakness	78.39	47.41	29	725	10220	1735807
Haemodialysis	78.21	47.41	21	733	2595	1743432
Myopathy	75.77	47.41	19	735	1794	1744233
Polymyositis	70.09	47.41	13	741	289	1745738
Aspartate aminotransferase increased	62.73	47.41	25	729	10731	1735296
Blood creatinine increased	59.72	47.41	26	728	13920	1732107
Alanine aminotransferase increased	56.19	47.41	24	730	12254	1733773
Hepatic enzyme increased	51.50	47.41	19	735	6602	1739425
Metabolic acidosis	51.40	47.41	18	736	5384	1740643
Chromaturia	50.62	47.41	15	739	2635	1743392

Pharmacologic Action:

Source	Code	Description
ATC	C10AB04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates
FDA EPC	N0000175596	Peroxisome Proliferator Receptor alpha Agonist
FDA MoA	N0000175375	Peroxisome Proliferator-activated Receptor alpha Agonists
FDA Chemical/Ingredient	N0000170118	PPAR alpha
CHEBI has role	CHEBI:35679	antilipemic drug
MeSH PA	D000963	Antimetabolites
MeSH PA	D065687	Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertriglyceridemia	indication	302870006
Primary Prevention of Coronary Heart Disease	indication
Hypoalphalipoproteinemia	off-label use	190785000
Primary biliary cirrhosis	contraindication	31712002	DOID:12236
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Acute nephropathy	contraindication	58574008
Leukopenia	contraindication	84828003	DOID:615
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Calculus in biliary tract	contraindication	266474003
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Breastfeeding (mother)	contraindication	413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.13	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN	AGONIST	EC50	4.23	IUPHAR	CHEMBL
Cytochrome P450 2C8	Enzyme	P10632	CP2C8_HUMAN		Ki	5.74	WOMBAT-PK
Lipoprotein lipase	Enzyme	P06858	LIPL_HUMAN				WOMBAT-PK
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		Ki	4.52	WOMBAT-PK
Transthyretin	Secreted	P02766	TTHY_HUMAN		Kd	7	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	5.73	CHEMBL

External reference:

ID	Source
4018639	VUID
N0000146952	NUI
C0017245	UMLSCUI
D00334	KEGG_DRUG
35282000	SNOMEDCT_US
523	MMSL
4719	RXNORM
387189002	SNOMEDCT_US
4778	MMSL
d00245	MMSL
4018639	VANDF
002050	NDDF
CHEBI:5296	CHEBI
CHEMBL457	ChEMBL_ID
Q8X02027X3	UNII
3899	INN_ID
DB01241	DRUGBANK_ID
3463	PUBCHEM_CID
D015248	MESH_DESCRIPTOR_UI
3439	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lopid	HUMAN PRESCRIPTION DRUG LABEL	1	0071-0737	TABLET, FILM COATED	600 mg	ORAL	NDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9130	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9707	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0615-3559	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-569	TABLET, FILM COATED	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	16714-101	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-732	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	24658-260	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	31722-225	TABLET	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	33261-146	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	42806-260	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	12 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-090	TABLET, FILM COATED	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-772	TABLET, FILM COATED	600 mg	ORAL	ANDA	13 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2450	TABLET, FILM COATED	600 mg	ORAL	ANDA	10 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2902	TABLET	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50268-350	TABLET	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	51138-588	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	51655-142	TABLET	600 mg	ORAL	ANDA	9 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53002-1068	TABLET	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2068	TABLET, FILM COATED	600 mg	ORAL	ANDA	10 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53217-251	TABLET	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0251	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0368	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0673	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0838	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0863	TABLET, FILM COATED	600 mg	ORAL	ANDA	12 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2353	TABLET, FILM COATED	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	55700-493	TABLET	600 mg	ORAL	ANDA	11 sections